LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
LifeMD, Inc.NASDAQ: LFMD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$6.88M, compared with $5.2M a year earlier. Trailing-twelve-month EBITDA was -$4.22M.
Context
- EBITDA amounted to 0.8% of revenue in FY2025, down 2.3 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$16.46M (-985.2%) for the fiscal year ending Dec 2026, a slowdown from the +77.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.88M-884.9% QoQ
- Last fiscal yearDec 2025
- -$1.52M+77.2% YoY
- LTMMar 2026
- -$4.22M-227.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -232.2% | -360.0% | -127.8 pp |
| 1 year | +77.2% | -985.2% | -1062.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (1.52M) USD
- Year-over-year change
- +77.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.52M) | +77.2% |
| FY2024 | 2024-12-31 | (6.65M) | +19.0% |
| FY2023 | 2023-12-31 | (8.21M) | +78.7% |
| FY2022 | 2022-12-31 | (38.6M) | +33.4% |
| FY2021 | 2021-12-31 | (57.94M) | — |
EBITDA vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -227.5% is the lowest of 10, against a peer median of +5.3%.
- EBITDA amounts to 1.9% of revenue for LFMD, versus a peer median of 23.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.57M USD | -26.5% | -3.8% | 9.4% | |
| LTM Mar 2026 | $8.33M USD | +748.5% | — | 7.7% | |
| LTM Mar 2026 | $1.19M USD | +114.0% | — | 0.5% | |
| LTM Mar 2026 | -$4.22M USD | -227.5% | — | 1.9% | |
| LTM Apr 2026 | -CA$6.09M CAD | -121.9% | — | 0.9% | |
| LTM Mar 2026 | -$9.96M USD | +38.2% | — | 23.8% | |
| LTM Mar 2026 | -$26.57M USD | +5.3% | — | 46.0% | |
| LTM Mar 2026 | -$31.68M USD | +27.7% | — | 39.8% | |
| LTM Mar 2026 | -$45.97M USD | -0.0% | — | 77.8% | |
| LTM Mar 2026 | -$80.8M USD | -25.3% | — | 198.5% | |
| Peer median (excluding LFMD) | — | +5.3% | -3.8% | 23.8% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 92.88M | 119.03M | 152.55M | 212.45M | 194.06M |
| Cost of Revenue | 18M | 18.67M | 18.9M | 24.07M | 39.29M |
| Gross Profit | 74.88M | 100.37M | 133.65M | 188.39M | 154.76M |
| Gross Margin | 80.6% | 84.3% | 87.6% | 88.7% | 79.8% |
| Research & Development | 948.16K | 2.97M | 6.06M | 9.51M | 7.35M |
| Selling, General & Admin | 122.08M | 125.33M | 128.15M | 175.68M | 144.01M |
| Operating Expenses | 129.18M | 143.81M | 148.14M | 204.53M | 162.43M |
| Depreciation & Amortization | 355.87K | 1.09M | 6.6M | 9.49M | 7.31M |
| EBITDA | (57.94M) | (38.6M) | (8.21M) | (6.65M) | (1.52M) |
| EBITDA Margin | -62.4% | -32.4% | -5.4% | -3.1% | -0.8% |
| Operating Income | (54.3M) | (43.45M) | (14.49M) | (16.14M) | (7.67M) |
| Operating Margin | -58.5% | -36.5% | -9.5% | -7.6% | -4.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.02M | 1.28M | 2.6M | 2.18M | 1.36M |
| Other Income / Expenses | (7.02M) | (1.21M) | (2.92M) | (2.18M) | (2.52M) |
| Income Before Tax | (61.32M) | (44.66M) | (17.41M) | (18.33M) | (10.19M) |
| Pre-Tax Margin | -66.0% | -37.5% | -11.4% | -8.6% | -5.2% |
| Income Tax Expense | 7.7K | 360.7K | 428K | 402K | 45.72K |
| Net Income | (60.9M) | (45.54M) | (20.6M) | (18.88M) | (7.11M) |
| Net Margin | -65.6% | -38.3% | -13.5% | -8.9% | -3.7% |
| EPS (Basic) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| EPS (Diluted) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| Weighted Avg Shares | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
| Weighted Avg Shares (Diluted) | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.